129. 48
After Hours
129. 45
-0.03 -0.02%
318.6B Market Cap
58.39 P/E Ratio
3.08% Div Yield
7,338,200 Volume
1.46 Eps
$ 129.37
Previous Close
Day Range
128.65 129.87
Year Range
99.14 133.1

MRK Chart

Merck & Co Inc Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Robert M. Davis J.D. CEO
NYSE Exchange
US58933Y1055 ISIN
US Country
70,000 Employees
- Last Dividend
- Last Split
13 Jan 1978 IPO Date


Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.

Products and Services

The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:

  • Keytruda: A forefront immunotherapy for treating various types of cancer.
  • Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia: A portfolio of pharmaceuticals addressing hospital acute care, neuroscience, virology, cardiovascular, and diabetes.
  • Vaccine Products: Including preventive pediatric, adolescent, and adult vaccines with prominent products like Gardasil/Gardasil 9 for HPV, ProQuad, M-M-R II, and Varivax for measles, mumps, rubella, and chickenpox, RotaTeq for rotavirus, Vaxneuvance for pneumococcal infections, Pneumovax 23 for pneumonia, and Vaqta for hepatitis A.
  • Animal Health Solutions: Veterinary pharmaceuticals, vaccines, health management solutions and services, along with digitally connected identification, traceability, and monitoring products aimed at veterinarians, distributors, animal producers, farmers, and pet owners.

In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline:

  • Daiichi Sankyo's deruxtecan ADC candidates: A development and commercialization agreement covering patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for treating multiple solid tumors.
  • AstraZeneca's Lynparza and Koselugo: Co-development and co-commercialization for multiple cancer types, enhancing Merck's portfolio in oncology.
  • Collaborations across the industry: Partnerships with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well as Moderna, Inc., aiming to explore and bring new treatments and vaccines to market.

Contact Information

Address: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
Phone: 908 740 4000